Merck & Co. Inc. has announced promising results from the Phase 1 KANDLELIT-001 study, which evaluated MK-1084, an investigational KRAS G12C inhibitor, in patients with advanced colorectal cancer and non-small cell lung cancer harboring KRAS G12C mutations. The study demonstrated a manageable safety profile and encouraging antitumor activity for MK-1084, both as a monotherapy and in combination with other treatments. In non-small cell lung cancer, MK-1084 in combination with KEYTRUDA showed an objective response rate $(ORR.AU)$ of 77% in untreated metastatic patients with PD-L1 expression, while as a monotherapy, it achieved an ORR of 38% in previously treated patients. The findings suggest significant potential for MK-1084 in addressing prevalent KRAS mutations in cancer, representing a promising advancement in Merck's oncology pipeline.